Author name: Leonardo Arias

Sanofi’s Orano Med-partnered radioligand therapy AlphaMedix achieved all primary efficacy endpoints, which included a measure of overall response rate, in the mid-stage ALPHAMEDIX-02 study.

The centerpiece of the deal is orelabrutinib, a BTK inhibitor in late-stage development for multiple sclerosis that Biogen once paid $125 million for but abandoned after less than two years of testing.

Executives from Stryker and Johnson & Johnson are on the hunt for deals, despite a turbulent environment, they said at AdvaMed’s The MedTech Conference.

At AdvaMed’s annual conference, CEO Scott Whitaker addressed policy issues around tariffs, FDA staff cuts and the ongoing government shutdown.

Six takeaways from the CMS administrator’s appearance at a D.C. think tank Monday — including who’s set to be the next Medicaid director.

The $48 million award, granted through the Advanced Research Projects Agency for Health, will help Kernal take its in vivo mRNA-encoded CAR T therapy forward.

In the Phase III FIBRONEER-IPF study, Jascayd demonstrated significant lung capacity improvements over placebo.

Se ha identificado un enorme crecimiento acelerado en un planeta errante. A diferencia de los planetas de nuestro sistema solar y otros, los planetas errantes no están en órbita a ningún astro. Las nuevas observaciones, realizadas con el VLT (Very Large Telescope) del Observator …

The U.S. government remains shut down, with the FDA closed for new drug applications until further notice; cell and gene therapy leaders gather for the annual meeting in Phoenix with the field in a state of flux; Pfizer and Amgen will make drugs available at a discount as President Donald Trump’s tariffs still loom; and

Un estudio reciente ha suministrado datos nuevos y reveladores sobre uno de los grandes enigmas de la microbiología: ¿por qué sólo algunas cepas de bacterias comunes se convierten en agentes pandémicos? El estudio se centra en la Vibrio cholerae, la bacteria causan …